X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs STRIDES SHASUN LTD - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH STRIDES SHASUN LTD PANACEA BIOTECH/
STRIDES SHASUN LTD
 
P/E (TTM) x 82.2 14.4 572.6% View Chart
P/BV x 1.8 1.9 94.0% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 PANACEA BIOTECH   STRIDES SHASUN LTD
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
STRIDES SHASUN LTD
Mar-16
PANACEA BIOTECH/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1491,413 10.5%   
Low Rs82848 9.7%   
Sales per share (Unadj.) Rs84.1353.3 23.8%  
Earnings per share (Unadj.) Rs-18.323.4 -78.3%  
Cash flow per share (Unadj.) Rs-6.741.0 -16.3%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs83.7320.4 26.1%  
Shares outstanding (eoy) m61.2589.35 68.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.43.2 42.9%   
Avg P/E ratio x-6.348.3 -13.1%  
P/CF ratio (eoy) x-17.227.6 -62.5%  
Price / Book Value ratio x1.43.5 39.1%  
Dividend payout %021.4 0.0%   
Avg Mkt Cap Rs m7,074100,988 7.0%   
No. of employees `0002.84.7 58.6%   
Total wages/salary Rs m1,4494,988 29.1%   
Avg. sales/employee Rs Th1,874.16,730.0 27.8%   
Avg. wages/employee Rs Th527.01,063.6 49.5%   
Avg. net profit/employee Rs Th-407.7445.5 -91.5%   
INCOME DATA
Net Sales Rs m5,15431,564 16.3%  
Other income Rs m1001,212 8.2%   
Total revenues Rs m5,25432,776 16.0%   
Gross profit Rs m-7665,213 -14.7%  
Depreciation Rs m7111,573 45.2%   
Interest Rs m1,5031,803 83.4%   
Profit before tax Rs m-2,8813,049 -94.5%   
Minority Interest Rs m11127 8.5%   
Prior Period Items Rs m-6-27 21.2%   
Extraordinary Inc (Exp) Rs m1,771-371 -477.4%   
Tax Rs m17689 2.4%   
Profit after tax Rs m-1,1212,089 -53.7%  
Gross profit margin %-14.916.5 -90.0%  
Effective tax rate %-0.622.6 -2.6%   
Net profit margin %-21.86.6 -328.7%  
BALANCE SHEET DATA
Current assets Rs m3,81035,949 10.6%   
Current liabilities Rs m8,36519,402 43.1%   
Net working cap to sales %-88.452.4 -168.6%  
Current ratio x0.51.9 24.6%  
Inventory Days Days15671 219.6%  
Debtors Days Days67127 53.0%  
Net fixed assets Rs m14,48034,478 42.0%   
Share capital Rs m61894 6.9%   
"Free" reserves Rs m90322,601 4.0%   
Net worth Rs m5,12728,632 17.9%   
Long term debt Rs m5,83227,455 21.2%   
Total assets Rs m19,43376,591 25.4%  
Interest coverage x-0.92.7 -34.1%   
Debt to equity ratio x1.11.0 118.6%  
Sales to assets ratio x0.30.4 64.4%   
Return on assets %2.05.1 38.6%  
Return on equity %-21.97.3 -299.7%  
Return on capital %3.68.2 44.5%  
Exports to sales %24.548.1 50.9%   
Imports to sales %10.214.5 70.4%   
Exports (fob) Rs m1,26415,192 8.3%   
Imports (cif) Rs m5254,565 11.5%   
Fx inflow Rs m1,53916,612 9.3%   
Fx outflow Rs m9425,292 17.8%   
Net fx Rs m59711,320 5.3%   
CASH FLOW
From Operations Rs m599717 83.6%  
From Investments Rs m-438-22,284 2.0%  
From Financial Activity Rs m-30329,488 -1.0%  
Net Cashflow Rs m-1418,073 -1.8%  

Share Holding

Indian Promoters % 74.5 27.7 269.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 37.8 1.6%  
FIIs % 1.3 8.6 15.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 25.9 91.1%  
Shareholders   10,259 56,241 18.2%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   GSK PHARMA  ASTRAZENECA PHARMA  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Realty & Pharma Stocks Lead(09:30 am)

Asian stock indices are trading mixed today. The Shanghai Composite is lower by 0.29% while the Hang Seng is even. The Nikkei 225 is trading higher by 0.46%.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 23, 2017 10:34 AM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - UNICHEM LAB COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS